⌑ I · The MechanismHow it actually works.
Nicotinamide adenine dinucleotide (NAD+) is one of the most essential coenzymes in mammalian biology. It exists in every cell, participates in over 500 enzymatic reactions, and serves dual roles: as an electron carrier in cellular respiration (the oxidative phosphorylation pathway that produces ATP), and as a substrate for signaling enzymes including the sirtuins (SIRT1-7) and PARP proteins involved in DNA repair and stress response.[1]
NAD+ levels decline with age across nearly every tissue studied. The magnitude varies (10-50% reductions between age 30 and 70 in most measurements), but the trend is remarkably consistent. The causes of this decline are less resolved: decreased synthesis, increased consumption by CD38 (a NAD+-consuming enzyme that rises with age and inflammation), and reduced substrate availability all contribute.[1][2]
The hypothesis — this is important — is that age-related NAD+ decline drives some of the functional decline of aging (mitochondrial dysfunction, DNA damage accumulation, sirtuin underactivation), and that restoring NAD+ levels via precursor supplementation could reverse or slow these processes. It is a plausible hypothesis. It is not yet a validated therapy.[3]
NAD+ itself is not absorbed intact when taken orally — it's degraded in the gut. Supplementation uses NAD+ precursors that survive absorption and are converted intracellularly: nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), niacin (nicotinic acid), and nicotinamide (NAM). Each precursor takes a slightly different metabolic path. NMN and NR are the two commercially promoted forms.
⌑ II · The EvidenceWhat the research actually shows.
- Mouse studies (the origin story). Mills et al. (2016) and multiple subsequent studies from Sinclair, Imai, and other groups showed NMN administration in aged mice improved insulin sensitivity, aerobic capacity, mitochondrial function, and (in some studies) modestly extended healthspan. The mouse data is what launched the commercial interest.[4]
- Human NAD+ elevation — reliable. Multiple trials confirm that oral NMN or NR raise blood or tissue NAD+ levels in humans by 40-100%, dose-dependently, within 2-4 weeks. That the precursor works AS A PRECURSOR is not in question.[5]
- Human functional outcomes — mixed. This is where enthusiasm and evidence diverge. Notable human RCTs:
- Yoshino et al. (2021, Science) — NMN 250 mg/day for 10 weeks in prediabetic postmenopausal women improved muscle insulin sensitivity but not other metabolic markers.[6]
- Yamane et al. (2023) — NMN in older adults over 12 weeks: modest improvements in grip strength and walking speed; not all secondary endpoints reached significance.[7]
- Katayoshi et al. (2023) — NMN in healthy adults: elevated NAD+ confirmed; NO significant effect on aerobic capacity, mitochondrial markers, or fatigue in the trial period.[8]
- No longevity RCT in humans. There is not — and will not likely be for years — a randomized trial with lifespan or major morbidity endpoints. Everything about "NAD+ for longevity" in humans is currently extrapolation from mouse data and mechanistic reasoning.
- Safety — good so far. Human trials up to 1 g/day for 8-12 weeks report excellent tolerability. Long-term safety (years of use, higher doses, older adults) is inadequately characterized.[9]
⌑ III · The ProtocolHow it's actually used.
Common precursor dose
- NMN: 250-1000 mg once daily, most commonly 500 mg
- Nicotinamide riboside (NR): 250-500 mg once daily (Niagen brand)
- Niacin (nicotinic acid): 100-500 mg — well-established as a NAD+ raiser, dirt cheap, but produces flushing at higher doses
Timing
Morning dosing is common, on the theory that NAD+ is naturally higher during active periods and lower during sleep. Some practitioners recommend taking it with resveratrol or other polyphenols under the sirtuin-activation hypothesis. Direct clinical evidence for timing optimization is weak.
Duration
Serum NAD+ elevation is transient — levels return to baseline within days of stopping. Chronic use is the assumption for anyone pursuing the mechanism.
Sublingual vs oral
Sublingual NMN is marketed as bypassing gut degradation. Direct comparison studies suggest oral absorption is adequate at typical doses; the sublingual advantage is marketing-driven more than data-driven. Recent evidence suggests NMN is well-absorbed orally regardless of formulation.[5]
⌑ IV · Form SelectionNMN vs. NR vs. plain niacin.
NMN (nicotinamide mononucleotide)
The most hyped precursor. Marketed as the "closest to NAD+" (one enzymatic step away). Priced at $50-100/month for typical doses. FDA declared NMN not eligible as a dietary supplement in 2022, though enforcement has been limited — legal status is currently ambiguous.[9]
Nicotinamide riboside (NR)
Sold as Niagen (ChromaDex). Well-characterized safety, extensive human trials for pharmacokinetics. Similar NAD+ elevation to NMN. Clearer regulatory status as a supplement. Priced comparably to NMN.[5]
Niacin (nicotinic acid)
The cheapest NAD+ precursor by orders of magnitude ($5/month vs $50+). Effective at raising NAD+. Also has independent cardiovascular effects (raises HDL, lowers triglycerides, lowers Lp(a) — the historical niacin data). Produces flushing at higher doses (mediated by GPR109A, harmless but uncomfortable). The best-established precursor with the worst marketing.[1]
Nicotinamide (NAM)
Also raises NAD+. Well-established dermatology use. Long-term high-dose NAM can inhibit sirtuins directly, which may partly negate the mechanism you're supplementing to activate. Less popular as a longevity precursor for this reason.
The NMN market exists in significant part because it's premium-priced and patentable in specific formulations. Nicotinic acid raises NAD+ almost as reliably at a fraction of the cost. The bench science is genuinely interesting; the commercial packaging is where "engineered, not generated" runs into "marketed, not measured."
⌑ V · ConsiderationsWhat to watch for.
- Regulatory uncertainty (NMN). FDA's 2022 position statement declared NMN not a lawful supplement ingredient. Enforcement has been limited but the legal status is uncertain and could shift.[9]
- Cancer risk (theoretical). Some tumors upregulate NAD+ metabolism to support their metabolic demands. Mechanistic concerns about supplementing patients with active malignancy have been raised. No clinical evidence of increased cancer incidence in NAD+ precursor users, but caution warranted.[1]
- Niacin flushing. Immediate-release niacin at doses over 100 mg produces flushing lasting 30-60 minutes. Not harmful but uncomfortable. Extended-release formulations reduce flushing but have been associated with hepatotoxicity at high doses.
- NAM sirtuin inhibition. Nicotinamide at high chronic doses can directly inhibit sirtuins, potentially working against the longevity mechanism it's marketed for.[1]
⌑ VI · Codex VerdictThe honest read.
NAD+ precursor supplementation reliably raises NAD+. It is well-tolerated in human trials. The mechanistic case for longevity relevance is genuine and interesting. And — critically — human RCTs have not yet shown the kind of clean functional outcomes (aerobic capacity, insulin sensitivity, muscle function) that would justify the certainty with which the category is marketed.
The gap between "we raised your NAD+" and "you will live longer or healthier" is exactly where the wellness industry has been comfortable planting its flag. The Codex is not comfortable planting its flag there.
For someone with resources and interest in exploring the mechanism early, the risk profile appears low. For someone considering NMN as a proven longevity intervention, the evidence does not yet justify that framing. Plain niacin remains the most cost-effective way to raise NAD+ if the mechanism is what you're after.